| Status | Study |
| Recruiting |
Study Name: GLIDE Regiment Followed by ASCT for Aggressive NK/T Cell Lymphoma Condition: Lymphoma, Extranodal NK-T-Cell Date: 2017-05-02 Interventions: Drug: GLIDE The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8 |
| Recruiting |
Study Name: Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients Condition: Extranodal NK-T-Cell Lymphoma, Nasal Type Date: 2017-03-09 Interventions: Combination Product: L-Asparaginase or or Pegaspargase containing chemotherapy Patients receive at least |
| Not yet recruiting |
Study Name: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma Condition: Lymphoma, Extranodal NK-T-Cell Date: 2017-02-09 Interventions: Device: 18F-FDG PET/ CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
| Not yet recruiting |
Study Name: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma Condition: Lymphoma, Extranodal NK-T-Cell Date: 2017-02-09 Interventions: Device: 18F-FDG PET/CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
| Recruiting |
Study Name: T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Condition: Lymphoma, Large-Cell, Anaplasitc Hodgkin Disease Lymphoma, Date: 2017-02-09 Interventions: Biological: Anti-CD30-CAR T cells |
| Not yet recruiting |
Study Name: Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation Condition: Lymphoma, Extranodal NK-T-Cell EBV Date: 2016-08-20 Interventions: Drug: Chidamide BIW Chidamide |
| Recruiting |
Study Name: Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Condition: T-cell Non-Hodgkin Lymphoma Lymphoma, Extranodal NK-T-Cell Date: 2016-08-04 Interventions: Drug: Busulfan intravenous, 3. |
| Terminated |
Study Name: Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma Condition: Extranodal NK-T-CELL LYMPHOMA Date: 2016-06-09 Interventions: Drug: GIFOX-Bortezomib GIFOX-B |
| Recruiting |
Study Name: MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma Condition: Extranodal NK-T-Cell Lymphoma, Nasal Type Date: 2016-04-29 Interventions: Drug: MEDA |
| Recruiting |
Study Name: GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma Condition: Extranodal NK-T-Cell Lymphoma, Nasal Type Date: 2016-04-05 Interventions: Drug: GELAD Gemcitabine, 1.0g/ |